These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32648810)

  • 1. Efficacy and safety of brexpiprazole in patients with schizophrenia presenting with severe symptoms:
    Meade N; Shi L; Meehan SR; Weiss C; Ismail Z
    J Psychopharmacol; 2020 Aug; 34(8):829-838. PubMed ID: 32648810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Brexpiprazole on Agitation and Hostility in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies.
    Citrome L; Ouyang J; Shi L; Meehan SR; Baker RA; Weiss C
    J Clin Psychopharmacol; 2019; 39(6):597-603. PubMed ID: 31652166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia.
    Forbes A; Hobart M; Ouyang J; Shi L; Pfister S; Hakala M
    Int J Neuropsychopharmacol; 2018 May; 21(5):433-441. PubMed ID: 29415258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar mania.
    Vieta E; Sachs G; Chang D; Hellsten J; Brewer C; Peters-Strickland T; Hefting N
    J Psychopharmacol; 2021 Aug; 35(8):971-982. PubMed ID: 33691517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Brexpiprazole on Functioning in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies.
    Correll CU; He Y; Therrien F; MacKenzie E; Meehan SR; Weiss C; Hefting N; Hobart M
    J Clin Psychiatry; 2022 Mar; 83(2):. PubMed ID: 35235720
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52-week, open-label study.
    Ishigooka J; Iwashita S; Tadori Y
    Psychiatry Clin Neurosci; 2018 Jun; 72(6):445-453. PubMed ID: 29582518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies.
    Marder SR; Hakala MJ; Josiassen MK; Zhang P; Ouyang J; Weiller E; Weiss C; Hobart M
    Acta Neuropsychiatr; 2017 Oct; 29(5):278-290. PubMed ID: 27846922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study.
    Ishigooka J; Iwashita S; Tadori Y
    Psychiatry Clin Neurosci; 2018 Sep; 72(9):692-700. PubMed ID: 29774628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials.
    Grossberg GT; Kohegyi E; Mergel V; Josiassen MK; Meulien D; Hobart M; Slomkowski M; Baker RA; McQuade RD; Cummings JL
    Am J Geriatr Psychiatry; 2020 Apr; 28(4):383-400. PubMed ID: 31708380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial.
    Correll CU; Skuban A; Ouyang J; Hobart M; Pfister S; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
    Am J Psychiatry; 2015 Sep; 172(9):870-80. PubMed ID: 25882325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
    Thase ME; Youakim JM; Skuban A; Hobart M; Zhang P; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
    J Clin Psychiatry; 2015 Sep; 76(9):1232-40. PubMed ID: 26301771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder.
    Bauer M; Hefting N; Lindsten A; Josiassen MK; Hobart M
    Acta Neuropsychiatr; 2019 Feb; 31(1):27-35. PubMed ID: 30223911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians' choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study.
    Correll CU; Shi L; Weiss C; Hobart M; Eramo A; Duffy RA; Weiller E; Baker RA
    CNS Spectr; 2019 Oct; 24(5):507-517. PubMed ID: 30306884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study.
    Hobart M; Skuban A; Zhang P; Josiassen MK; Hefting N; Augustine C; Brewer C; Sanchez R; McQuade RD
    Curr Med Res Opin; 2018 Apr; 34(4):633-642. PubMed ID: 29343128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator.
    McEvoy J; Citrome L
    Clin Schizophr Relat Psychoses; 2016; 9(4):177-86. PubMed ID: 26757416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia.
    Kane JM; Skuban A; Ouyang J; Hobart M; Pfister S; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
    Schizophr Res; 2015 May; 164(1-3):127-35. PubMed ID: 25682550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study.
    Fleischhacker WW; Hobart M; Ouyang J; Forbes A; Pfister S; McQuade RD; Carson WH; Sanchez R; Nyilas M; Weiller E
    Int J Neuropsychopharmacol; 2017 Jan; 20(1):11-21. PubMed ID: 27566723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study: Brexpiprazole d'appoint pour l'engagement dans la vie des patients souffrant de trouble dépressif majeur: une étude interventionnelle canadienne ouverte de phase 4.
    Therrien F; Ward C; Chokka P; Habert J; Ismail Z; McIntyre RS; MacKenzie EM
    Can J Psychiatry; 2024 Jul; 69(7):513-523. PubMed ID: 38425284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study.
    Citrome L; Ota A; Nagamizu K; Perry P; Weiller E; Baker RA
    Int Clin Psychopharmacol; 2016 Jul; 31(4):192-201. PubMed ID: 26963842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia:
    Marder SR; Meehan SR; Weiss C; Chen D; Hobart M; Hefting N
    Schizophr Bull Open; 2021 Jan; 2(1):sgab014. PubMed ID: 34901863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.